Skip to main content
Journal cover image

Bevacizumab therapy for glioblastoma: a passionate discussion.

Publication ,  Journal Article
Desjardins, A; Friedman, HS
Published in: CNS Oncol
January 2014

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CNS Oncol

DOI

EISSN

2045-0915

Publication Date

January 2014

Volume

3

Issue

1

Start / End Page

1 / 3

Location

England

Related Subject Headings

  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • Bevacizumab
  • Antibodies, Monoclonal, Humanized
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., & Friedman, H. S. (2014). Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol, 3(1), 1–3. https://doi.org/10.2217/cns.13.53
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.CNS Oncol 3, no. 1 (January 2014): 1–3. https://doi.org/10.2217/cns.13.53.
Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol. 2014 Jan;3(1):1–3.
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.CNS Oncol, vol. 3, no. 1, Jan. 2014, pp. 1–3. Pubmed, doi:10.2217/cns.13.53.
Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol. 2014 Jan;3(1):1–3.
Journal cover image

Published In

CNS Oncol

DOI

EISSN

2045-0915

Publication Date

January 2014

Volume

3

Issue

1

Start / End Page

1 / 3

Location

England

Related Subject Headings

  • Humans
  • Glioblastoma
  • Brain Neoplasms
  • Bevacizumab
  • Antibodies, Monoclonal, Humanized
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis